What's new

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024

Mar 17, 2025 - 14:46
 0
Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024
Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024
Read More

Tags:

Previous Article

BMW: 2025 margins to remain below target

Next Article

Go Outdoors rolls out body cameras to 25 stores

Related Posts

Human medicines European public assessment report (EPAR): Dimethyl fumarate Accord, dimethyl fumarate, Date of authorisation: 22/04/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 10, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Filsuvez, birch bark, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0541/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 13, 2025  0

Human medicines European public assessment report (EPAR): Uptravi, selexipag, Date of authorisation: 12/05/2016, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 17, 2025  0